Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 33 - 40 of 12142 results

Some Congressional Dissent to Trump Administration’s AI Chip Sales to China; FTC Cracks Down on AI Marketing Claims — AI: The Washington Report
August 29, 2025| Article| Viewpoint

As Congress Preps PAMA Reform Bill, Legislators Ask CMS to Delay Law's Implementation
August 28, 2025| News

How Bankruptcy Law Caps Landlords' Rejected Lease Claims
August 28, 2025| News

The PTAB Pendulum Swings: How IPR Denials are Reshaping Patent Owner and Challenger Strategies
August 28, 2025| Blog| Viewpoint

Practical Policies – Disparage Me Not
August 26, 2025| Podcast| Viewpoint

Should Your Company Use an IP Holding Company? Here’s What You Need to Know
August 25, 2025| News

Meta Platforms Inc.’s AI Policies Under Investigation and States Continue to Pursue AI Regulation - AI: The Washington Report
August 22, 2025| Article| Viewpoint

SEC’s Pharmaceutical Insider Trading Case Yields Quick Deals
August 19, 2025| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
